Clinical usefulness of the oral chemotherapy agent S-1 in heavily pre-treated patients with advanced or recurrent cervical cancer

详细信息    查看全文

• 作者：Terumi Tanigawa ; Maki Matoda ; Akiko Yamamoto…
• 关键词：Advanced or recurrent cervical cancer ; S ; 1 ; Oral chemotherapy ; Antitumor ; Activity
• 刊名：Archives of Gynecology and Obstetrics
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：293
• 期：3
• 页码：633-638
• 全文大小：458 KB
• 参考文献：1.Parkin DM, Bray F, Ferlay J, Pisani PCA (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108
  2.Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24(14):2137–2150
  3.Center for Cancer control Information Services, ganjoho.jp. http://​ganjoho.​jp/​ . Accessed 2014 March 6
  4.Hong JH, Tsai CS, Lai CH, Chang TC, Wang CC, Chou HH, Lee SP, Hsueh S (2004) Recurrent squamous cell carcinoma of cervix after definitive radiotherapy. Int J Radiat Oncol Biol Phys 60:249–257CrossRef PubMed
  5.Wang CJ, Lai CH, Huang HJ, Hong JH, Chou HH, Huang KG, Lin JD (1999) Recurrent cervical carcinoma after primary radical surgery. Am J Obstet Gynecol 181:518–524CrossRef PubMed
  6.Yamamoto K, Izumi R, Hasegawa K, Nakajima H, Ohashi K, Kudo R, Okuda H, Takahashi T, Origasa H, Sugimori H (2004) Adjuvant oral 5-fluorouracil for cervical cancer: Japanese Gynecologic Oncology Group report. Int J Oncol 24:1175–1179PubMed
  7.Miura K, Shirasaka T, Yamaue H, Sasaki I (2012) S-1 as a core anticancer fluoropyrimidine agent. Expert Opin Drug Deliv 9(3):273–286CrossRef PubMed
  8.Katsumata N, Hirai Y, Kamiura S, Sugiyama T, Kokawa K, Hatae M, Nishimura R, Ochiai K (2011) Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer. Ann Oncol 22:1353–1357PubMedCentral CrossRef PubMed
  9.Kimura Y, Kikkawa N, Iijima S, Kato T, Naoi Y, Hayashi T, Tanigawa T, Yamamoto H, Kurokawa E (2003) A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice. Gastric Cancer 6(Suppl 1):34–39CrossRef PubMed
  10.Tsukuda M, Kida A, Fujii M, Kono N, Yoshihara T, Hasegawa Y, Sugita M (2005) Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer. Br J Cancer 93:884–889PubMedCentral CrossRef PubMed
  11.Imamura H, Furukawa H, Kishimoto T, Nakae S, Inoue K, Tsukahara Y, Imano M, Yamazaki K, Okano S, Morimoto T, Sugihara S, Shimokawa T (2007) Phase II study of 2-week TS-1 administration followed by 1-week rest for gastric cancer. Hepatogastroenterology 54:2167–2171PubMed
  12.Hwang JH, Lim MC, Seo SS, Kang S, Park SY, Kim JY (2012) Outcomes and toxicities for the treatment of stage IVB cervical cancer. Arch Gynecol Obstet 285(6):1685–1693CrossRef PubMed
  13.Tian ZZ, Li S, Wang Y, Yue YJ, Zhu XH, Zhao R, Zhang CL, Wei SH (2014) Investigation of uterine arterial chemoembolization and uterine arterial infusion chemotherapy for advanced cervical cancer before radical radiotherapy: a long-term follow-up study. Arch Gynecol Obstet 290(1):155–162CrossRef PubMed
  14.Garcia AA, Blessing JA, Darcy KM, Lenz HJ, Zhang W, Hannigan E, Moore DH (2007) Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study. Gynecol Oncol 104:572–579PubMedCentral CrossRef PubMed
  15.Look KY, Blessing JA, Gallup DG, Lentz SS (1996) A phase II trial of 5-fluorouracil and high-dose leucovorin in patients with recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Am J Clin Oncol 19:439–441CrossRef PubMed
  16.Schilder RJ, Blessing J, Cohn DE (2005) Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 96:103–107CrossRef PubMed
  17.Coleman RE, Harper PG, Gallagher C, Osborne R, Rankin EM, Silverstone AC et al (1986) A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix. Cancer Chemother Pharmacol 18:280–283CrossRef PubMed
  18.Sutton GP, Blessing JA, McGuire WP, Patton T, Look KY (1993) Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study. Am J Obstet Gynecol 168:805–807CrossRef PubMed
  19.Verschraegen CF, Levy T, Kudelka AP, Llerena E, Ende K, Freedman RS, Edwards CL, Hord M, Steger M, Kaplan AL, Kieback D, Fishman A, Kavanagh JJ (1997) Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol Off J Am Soc Clin Oncol 15:625–631
  20.Bookman MA, Blessing JA, Hanjani P, Herzog TJ, Andersen WA (2000) Topotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 77:446–449CrossRef PubMed
  21.Muderspach LI, Blessing JA, Levenback C, Moore JL Jr (2001) A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 81:213–215CrossRef PubMed
  22.Muggia FM, Blessing JA, Method M, Miller DS, Johnson GA, Lee RB, Menzin A (2004) Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 92:639–643CrossRef PubMed
  23.Takatori E, Shoji T, Suga Y, Niinuma H, Miura Y, Kaido Y, Takada A, Kagabu M, Takeuchi S, Sugiyama T (2014) A pilot study of oxaliplatin with oral S-1 as second-line chemotherapy of patients with recurrent adenocarcinoma of the uterine cervix. Int J Clin Onclo 19(2):336–340CrossRef
  
• 作者单位：Terumi Tanigawa (1)
  Maki Matoda (1)
  Akiko Yamamoto (1)
  Hidetaka Nomura (1)
  Sanshiro Okamoto (1)
  Kimihiko Sakamoto (1)
  Eiji Kondo (1)
  Kohei Omatsu (1)
  Kazuyoshi Kato (1)
  Nobuhiro Takeshima (1)
  
  1. Department of Gynecology, Cancer Institute Hospital, 3-8-31 Ariake, Koutou-ku, Tokyo, 135-8550, Japan
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Gynecology
  Obstetrics and Perinatology
  Endocrinology
  Human Genetics
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-0711

文摘

Purpose Our aim was to evaluate the efficacy and safety of S-1 in heavily pre-treated patients with advanced (FIGO stage IVB) or recurrent cervical cancer.